Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04835506 · ClinicalTrials.gov registry record · Phase 4
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
A Phase 4 study of Ulcerative Colitis and Crohn Disease, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT04835506 is a Phase 4 study of Ulcerative Colitis and Crohn Disease that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 124 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04835506, a Phase 4 study of Ulcerative Colitis and Crohn Disease, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
The OPTIMIZE Trial compares whether iDose dashboard-driven infliximab dosing (iDose-driven dosing) is more effective and safer than standard infliximab dosing for inducing and maintaining disease remission in inflammatory bowel disease.
Conditions Studied
Interventions
- DRUG Infliximab
Study Locations (20)
Illinois
- University of Chicago Medicine - Chicago
- Northwestern University - Evanston
- Rockford GI - Rockford
Massachusetts
- Boston Children's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Lahey Hospital and Medical Center - Burlington
New York
- NYU Langone Health - New York
- Icahn School of Medicine at Mount Sinai - New York
- Weill Cornell Medical College - New York
Connecticut
- Yale University School of Medicine - New Haven
Florida
- University of Miami - Miami
Maryland
- University of Maryland Medical Center - Baltimore
Minnesota
- University of Minnesota - Minneapolis
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04835506
The ClinicalTrials.gov registry entry for NCT04835506 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (94% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Infliximab is the first listed.
NCT04835506 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Illinois, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04835506 about?
NCT04835506 is a clinical study titled "Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial". The OPTIMIZE Trial compares whether iDose dashboard-driven infliximab dosing (iDose-driven dosing) is more effective and safer than standard infliximab dosing for inducing and maintaining disease remission in inflammatory bowel disease.
What is the current status of trial NCT04835506?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 124 participants. The study started on 2021-11-01. Estimated completion is 2026-09.
What conditions does trial NCT04835506 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn Disease, Inflammatory Bowel Diseases.
What interventions are being tested in trial NCT04835506?
The interventions under investigation include: Infliximab (DRUG).
Who is sponsoring clinical trial NCT04835506?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04835506 being conducted?
This trial has 20 study locations across Connecticut, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 4
-
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
RECRUITING · Phase 4
-
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RECRUITING
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.